The DOI matches its Crossref record.
New drug development in the United States from 1963 to 1999
Abstract
Clinical Pharmacology & Therapeutics (2001) 69, 286–296; doi: 10.1067/mcp.2001.115132
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Self-citationInnovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Self-citationDrug development for neglected diseases: a deficient market and a public-health policy failure
Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09096-7 · Cited by 893
Key factors in the rising cost of new drug discovery and development
Dickson, M., & Gagnon, J. P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1382 · Cited by 498
Adipokines – removing road blocks to obesity and diabetes therapy
Blüher, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.005 · Cited by 273
Metadata
- Authors
- DiMasi, J. A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-05
- Volume
- 69
- Issue
- 5
- Pages
- 286-296
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2031723179
- Cited by
- 251
- References
- 0
- FWCI
- 26.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New drug development in the United States from 1963 to 1999. https://app.cochat.ai/papers/10.1067/mcp.2001.115132
- The paper
- DiMasi, J. A. (2001). New drug development in the United States from 1963 to 1999. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2001.115132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
